Look at Total Prescribing Info OPDIVO® (nivolumab) is indicated for that treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately after 3 or more lines of systemic therapy that includes autologous… Read More